Moxifloxacine Biogaran

Moxifloxacin, the active ingredient in Moxifloxacine Biogaran, is a fluoroquinolone antibiotic presented as an oral formulation for systemic use. It treats a range of bacterial infections, particularly respiratory and soft‑tissue infections, in adult patients. The drug works by inhibiting bacterial DNA replication, providing effective coverage against susceptible Gram‑negative and Gram‑positive organisms.

GNH USA supplies Moxifloxacine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Moxifloxacine Biogaran is a fluoroquinolone antibiotic indicated for several bacterial infections.

Community‑acquired pneumonia: achieves bacterial clearance and clinical recovery. Acute bacterial sinusitis: reduces sinus inflammation and eradicates causative pathogens. Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection. Skin and soft tissue infections: eliminates skin‑associated bacteria and promotes healing. Complicated intra‑abdominal infections: provides broad‑spectrum coverage to control intra‑abdominal sepsis.

Moxifloxacine Biogaran may cause a variety of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially Achilles. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis with watery diarrhea. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before prescribing Moxifloxacine Biogaran, clinicians should consider several safety measures.

Assess renal function: adjust use in patients with impaired kidney function. Monitor for tendon pain: discontinue if signs of tendonitis appear. Avoid concomitant QT‑prolonging drugs: reduce risk of cardiac arrhythmias. Use with caution in patients with known cardiac arrhythmias: monitor ECG as needed. Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacine Biogaran can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Other fluoroquinolones (e.g., ciprofloxacin): additive risk of tendon rupture. - Antacids containing magnesium or aluminum: reduce oral absorption of moxifloxacin. - Warfarin: may increase anticoagulant effect and bleeding risk. - CYP450 inducers (e.g., rifampicin): decrease plasma concentrations of moxifloxacin.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened risk of tendon injury. - Theophylline: may raise theophylline plasma levels, causing toxicity. - Diabetes medications: potential alteration of glycemic control.